Small cell lung cancer · 6 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cisplatin and Etoposide (EP) Variant #01 | — | R 4 264 | 42d | 5.0 mo | 10.2 mo | 4 | R 17 056 PFS proxy | 10 |
VMV/VAC Variant #01 | — | R 2 666 | 21d | — | — | — | — | — |
Carboplatin and Etoposide (CE) Variant #10 | — | R 2 265 | 21d | 4.4 mo | 10.6 mo | 7 | R 15 853 PFS proxy | 16 |
CAV/PE Variant #01 | — | R 1 354 | 21d | — | — | — | — | — |
CAV Variant #01 | — | R 760 | 21d | — | ~7.6 mo | — | — | 1 |
MACC Variant #01 Partial | — | R 480 | 21d | — | — | — | — | — |
6 of 6 regimens shown